Radiologic aspects of immune-related tumor response criteria and patterns of immune-related adverse events in patients undergoing ipilimumab therapy

AJR Am J Roentgenol. 2011 Aug;197(2):W241-6. doi: 10.2214/AJR.10.6032.


Objective: The objective of this article is to illustrate examples of radiologic immune-related response criteria and toxicity in patients with advanced melanoma treated with the immunotherapeutic agent ipilimumab.

Conclusion: Novel immune-related tumor response criteria should be applied to patients undergoing therapy with ipilimumab for advanced melanoma. Ipilimumab also produces a spectrum of immune-related adverse effects that can be recognized radiologically.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / adverse effects*
  • Drug-Related Side Effects and Adverse Reactions / diagnostic imaging*
  • Drug-Related Side Effects and Adverse Reactions / immunology
  • Humans
  • Immunotherapy / adverse effects*
  • Ipilimumab
  • Melanoma / drug therapy*
  • Melanoma / immunology
  • Melanoma / pathology
  • Neoplasm Staging
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / immunology
  • Skin Neoplasms / pathology
  • Tomography, X-Ray Computed*


  • Antibodies, Monoclonal
  • Ipilimumab